Envestnet Asset Management
BLPH

Envestnet Asset Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Envestnet Asset Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-67
Closed -$1K – 3429
2016
Q3 		$1K Buy
+67
New +$1.62K ﹤0.01% 2894

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Envestnet Asset Management's BLPH Position: Q4 2016 in Review

Envestnet Asset Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2016, closing a stake of 67 shares — an estimated $1K sold.

Envestnet Asset Management first reported a position in BLPH in Q3 2016 and held it in 1 quarter. The position peaked at $1K in Q3 2016. 15 funds tracked by Wall St. Rank hold BLPH as of Q4 2016.

  • Envestnet Asset Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Envestnet Asset Management sold 67 Bellerophon Therapeutics, Inc. shares in Q4 2016, an estimated $1K.
  • Envestnet Asset Management first reported a position in Bellerophon Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Envestnet Asset Management's Bellerophon Therapeutics, Inc. position peaked at $1K in Q3 2016.
  • 15 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2016.

Based on Envestnet Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.